April 24, 2018 / 11:04 AM / a month ago

BRIEF-Alnylam Reports New Clinical Results From The Apollo Phase 3 Study Of Patisiran

April 24 (Reuters) - Alnylam Pharmaceuticals Inc:

* ALNYLAM REPORTS NEW CLINICAL RESULTS FROM THE APOLLO PHASE 3 STUDY OF PATISIRAN AT THE AMERICAN ACADEMY OF NEUROLOGY 2018 ANNUAL MEETING

* ALNYLAM PHARMA - IN NEW POST-HOC ANALYSIS, PATISIRAN REDUCED COMPOSITE RATE OF ALL-CAUSE HOSPITALIZATION, MORTALITY BY ABOUT 50%, RELATIVE TO PLACEBO

* ALNYLAM PHARMACEUTICALS INC - PATISIRAN DEMONSTRATED IMPROVEMENT IN MULTIPLE QUALITY OF LIFE MEASURES, COMPARED TO PLACEBO Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below